^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rezetamig (JNJ-8780)

    i
    Other names: JNJ-8780, JNJ-75348780
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    CD3 agonist, CD22 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=40, Recruiting, Janssen Research & Development, LLC
    New P1 trial • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    12ms
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2026 --> May 2025
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    1year
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
    Enrollment open • Trial completion date • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    1year
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2023 --> Apr 2025
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    1year
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Janssen Research & Development, LLC
    New P1 trial • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    1year
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    over1year
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2023 --> Oct 2023
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    over1year
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2025 --> Sep 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    almost2years
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=200, Recruiting, Janssen Research & Development, LLC | N=120 --> 200
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    2years
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2024 --> May 2025
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)
    almost3years
    A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2023 --> Sep 2023
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    rezetamig (JNJ-8780)